Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Mar. 24, 2026 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Mar. 31, 2026 |
Feb. 18, 2026 |
Dec. 31, 2025 |
Oct. 31, 2025 |
Feb. 28, 2023 |
|
| Equity Offering [Line Items] | ||||||||||
| Net proceeds from sale of common stock | $ 20,233 | $ 0 | ||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Description | As of June 30, 2026, we had 22,680,288 shares of common stock issued and outstanding. In addition, as of June 30, 2026 we had reserved (i) 474,615 shares of common stock for issuance upon the exercise of outstanding stock options, including shares reserved under unvested options, with a weighted-average exercise price of $59.06 per share; (ii) 5,209,631 shares of common stock for issuance upon the vesting of outstanding RSUs and PSUs (assuming all performance milestones are satisfied), (iii) 1,493,758 shares of common stock available for future issuance under our 2022 Equity Incentive Plan, 2022 Inducement Stock Incentive Plan, and 2013 Employee Stock Purchase Plan, in the aggregate; (iv) 14,043,996 shares of common stock for issuance upon the exercise of outstanding warrants, with a weighted-average exercise price of $11.71 per share, including 5,739,289 that expire on August 29, 2026 if not exercised; (v) 4,005,544 shares of common stock for issuance upon the exercise of outstanding pre-funded warrants; (vi) 11,904,630 shares of common stock for issuance upon conversion of the 2028 Notes and 2029 Notes, in the aggregate (assuming all make-whole adjustments and assuming payment in-kind of interest payments as permitted by the applicable indenture); and (vii) 5,000 shares of common stock issuable to Neumedicines Inc. upon the satisfaction of certain milestones under that certain Asset Purchase Agreement dated as of November 24, 2020. As of June 30, 2026, based on 106,000,000 shares of common stock authorized, we had 46,182,538 shares of common stock that were unissued and unreserved. | |||||||||
| Common stock, shares authorized | 106,000,000 | 106,000,000 | 106,000,000 | |||||||
| Common stock, shares issued | 22,680,288 | 22,680,288 | 18,311,000 | |||||||
| Common stock, shares outstanding | 22,680,288 | 22,680,288 | 18,311,000 | |||||||
| shares of common stock reserved for feature issuance | 474,615 | 474,615 | ||||||||
| Weighted-average exercise price | $ 59.06 | $ 59.06 | ||||||||
| Weighted average exercise price expiration | 5,739,289 | |||||||||
| Exercise price | $ 0.0001 | $ 0.0001 | $ 6.64 | |||||||
| Common stock unissued and unreserved | 46,182,538 | 46,182,538 | ||||||||
| 2028 Notes and 2029 Notes | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Common stock, shares issued | 11,904,630 | 11,904,630 | ||||||||
| Securities Purchase Agreement [Member] | Private Placement [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Common stock, shares issued | 1,030,354 | |||||||||
| Securities Purchase Agreement [Member] | 2026 Warrants [Member] | Private Placement [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Net proceeds from sale of common stock | $ 26,900 | |||||||||
| Common stock purchased with warrants | 4,421,518 | |||||||||
| Exercise price | $ 10 | |||||||||
| Pre-Funded Warrants [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Common stock, shares issued | 4,005,544 | 4,005,544 | 3,391,164 | 2,913,136 | ||||||
| Common stock purchased with warrants | 956,885 | |||||||||
| Exercise price | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||
| Outstanding Warrant | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Common stock, shares issued | 14,043,996 | 14,043,996 | ||||||||
| Weighted-average exercise price | $ 11.71 | $ 11.71 | ||||||||
| Jefferies LLC [Member] | Open Market Sale Agreement [Member] | Common Stock [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Number of shares of common stock issued | 0 | 0 | 2,994,441 | 0 | ||||||
| Net proceeds from sale of common stock | $ 100,000 | |||||||||
| Net proceeds from common stock | $ 19,800 | |||||||||
| Neumedicines Inc | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Common stock, shares issued | 5,000 | 5,000 | ||||||||
| RSUs and PSUs | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Common stock, shares issued | 5,209,631 | 5,209,631 | ||||||||
| 2022 Equity Incentive Plan, 2022 Inducement Stock Incentive Plan and 2013 Employee Stock Purchase Plan | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| common stock available for future issuance | 1,493,758 | 1,493,758 | ||||||||
| Maximum [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Capital stock, shares authorized | 111,000,000 | |||||||||
| Common stock, shares authorized | 106,000,000 | |||||||||
| Maximum [Member] | Pre-Funded Warrants [Member] | Securities Purchase Agreement [Member] | Private Placement [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Common stock, shares issued | 3,391,164 | |||||||||
| Maximum [Member] | Jefferies LLC [Member] | Open Market Sale Agreement [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Aggregate offering price | $ 100,000 | |||||||||
| Percentage of commission of gross proceeds from the sale of Shares | 3.00% | |||||||||
| Minimum [Member] | ||||||||||
| Equity Offering [Line Items] | ||||||||||
| Capital stock, shares authorized | 58,333,333 | |||||||||
| Common stock, shares authorized | 53,333,333 | |||||||||